Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension
NCT02104245 is registered in ClinicalTrials.gov with Aradigm Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension
- Lead sponsor
- Aradigm Corporation
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 28, 2014
- Completion date
- October 31, 2016
- Enrollment
- 304 (actual)
- Sites
- 95
Conditions
As the registry lists them; a condition with its own page is linked.
non cystic fibrosis bronchiectasis